Zydus Lifesciences gained 1.49% to Rs 1130.50 after it received final approval from the United States Food and Drug Administration (USFDA) to market Amantadine extended-release capsules, 68.5 mg, and tentative approval for 137 mg.
The approved drug is a reference listed drug of Gocovri (amantadine) extended-release capsules, 68.5 mg and 137 mg.
The Amantadine extended-release capsules are indicated for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
The drug will be manufactured at the groups formulation manufacturing facility in Ahmedabad SEZ-II, India.
This approval makes Zydus eligible for 180 days of exclusivity for Amantadine extended-release capsules, 68.5 mg.
Also Read
 "SpaceX rocket")
 "Protest, kolkata protest, Kolkata March, Howrah March")
 "Challa Sreenivasulu Setty")
 "ipo market listing share market")
 "Carlos Alcaraz, Carlos, Alcaraz")
The group now has 400 approvals and has so far filed over 465 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharma companys consolidated net profit surged 30.64% to Rs 1,419.9 crore in Q1 FY25 as compared to Rs 1,086.9 crore posted in Q1 FY24. Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quarter ended 30 June 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
